First Berlin reiterates Buy on CEL-SCI, cuts price target to USD 15

Reuters2026/07/20 13:58

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

First Berlin reiterated a Buy on CEL-SCI, cut its 12-month target price to USD 15 from USD 60.
Report flagged a May 11 partnership with Saudi drugmaker Amarox to pursue Multikine registration and commercialization in Saudi Arabia, with optional GCC expansion.
Terms include Amarox leading SFDA regulatory work, a 50/50 net revenue split, CEL-SCI retaining IP and global rights.
Analyst highlighted a 212-patient FDA confirmatory registration study, with enrollment expected to start soon in a defined head and neck cancer subgroup.
First Berlin cited May and June financings totaling about USD 9.7 million, noting most funding for the study still needs to be raised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EQS News (Ref. ID: rc_26222) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

First Berlin reiterates Buy on CEL-SCI, cuts price target to USD 15

You may also like

Crypto prices